Silence Therapeutics Announces Oversubscribed $120 Million Private Placement Posted on February 5, 2024September 26, 2024 by Kate Schykerynec
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing Posted on February 5, 2024September 26, 2024 by Kate Schykerynec
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older Posted on December 15, 2023September 26, 2024 by Kate Schykerynec
